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ABSTRACT: The present monograph reviews data relevant to applying the biowaiver procedure for the approval of immediate-release
multisource solid dosage forms containing codeine phosphate. Both biopharmaceutical and clinical data of codeine were assessed.
Solubility studies revealed that codeine meets the “highly soluble” criteria according to World Health Organization (WHO), the European
Medicines Agency (EMA), and the United States Food and Drug Administration (US FDA). Codeine’s fraction of dose absorbed in humans
was reported to be high (>90%) based on cumulative urinary excretion of drug and drug-related material following oral administration.
The permeability of codeine was also assessed to be high in both Caco-2 monolayers and rat intestinal perfusion studies. The main risks
associated with codeine, that is, toxicity (attributed to CYP2D6 polymorphism) and its abuse potential, are present irrespective of the
dosage form, and do not need to be taken into account for bioequivalence (BE) considerations. Taken together, codeine is a class 1 drug
with manageable risk and is a good candidate for waiver of in vivo BE studies. C© 2014Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci 103:1592–1600, 2014
Keywords: absorption; bioavailability; bioequivalence; biopharmaceutics classification system (BCS); codeine phosphate; permeability;
dissolution; solubility
INTRODUCTION
The present biowaiver monograph addresses the active phar-
maceutical ingredient (API) codeine phosphate. This mono-
graph is a part of the biowaiver monograph series by the
International Pharmaceutical Federation (FIP) that currently
contains over 40 monographs (http://www.fip.org/bcs). The pur-
pose of this series is to assess whether in vivo pharmacoki-
netic bioequivalence (BE) studies can be safely waived in fa-
vor of in vitro dissolution studies for the approval of new
immediate-release (IR) solid oral dosage forms of a given API.
Eachmonograph is based on a comprehensive literature review,
which forms the basis of the risk–benefit analysis of applying
a biowaiver-based approval to new or extensively revised for-
mulations of the given API. Some of the properties discussed
include the solubility of the API, pharmacokinetics and perme-
ability data, the therapeutic use and therapeutic index, data
on excipient interactions, and any problems that have been
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reported with bioavailability (BA) and/or BE. On the basis of
these properties, a risk–benefit analysis is performed and a de-
cision to recommend or advise against biowaivers for the given
API is made.
GENERAL CHARACTERISTICS
Scope
This monograph refers exclusively to the phosphate salt of
codeine. The analysis is relevant primarily for oral formulations
in which codeine phosphate is the sole active ingredient; it may
also be applied for combination products containing codeine
phosphate. However, for combination products, the other APIs
and their potential interaction with codeine phosphate should
be analyzed as well. Modified/extended release formulations
are also out of the scope of this analysis.
Name
Codeine is an opioid derived from the unripe seed capsules
of the poppy plant (Papaver somniferum), and it has a sim-
ilar structure to morphine, with a methyl substitution on the
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Figure 1. Molecular structure of codeine.
phenolic hydroxyl group.1 The chemical description of the phos-
phate salt form is 7,8-didehydro-4,5 alpha-epoxy-3-methoxy-
17-methylmorphinan-6 alpha-ol phosphate (1:1) and has the
molecular formula of C18H21NO3·H3PO4·1/2H2O. Codeine has
one chiral center. Its molecular weight is 406.4 g/mol and its
melting point is 155◦C (Merck Index). The structure of codeine
phosphate is given in Figure 1.
Therapeutic Indication and Dose
Codeine phosphate demonstrated antitussive activity in sev-
eral clinical trials performed between 1966 and 1984.2 Al-
though this effect was observed in patients suffering from
chronic cough as a result of diseases such as bronchitis or
chronic obstructive pulmonary disease, the prescription of
codeine for acute cough has become a common practice over the
years. However, more recent studies failed to demonstrate any
antitussive effect of this drug when compared with placebo.3,4
Therefore, codeine phosphate is currently recommended by the
American College of Chest Physician (ACCP) for the alleviation
of chronic but not acute cough.5 Reports in the literature on the
daily dose of codeine required for cough suppression ranges
between 7.5 and 60 mg.5
Codeine is also indicated for the relief of mild to moderately
severe pain. The analgesic properties of codeine stem from its
conversion to morphine and morphine-6-glucuronide because
codeine’s affinity for :-opioid receptors is 200-fold weaker than
that of morphine.6,7 Codeine has one chiral center, and some
data suggest stereospecific analgesic (but not antitussive) effect
of the d- and l-isomers.8 Yet, to the best of our knowledge, all
marketed products include the racemic mixture of codeine. The
recommended initial dose for pain relief is 15–30 mg every 6 h.
This dose can be increased in increments of 15–30 mg per day
up to a total daily dose of 600 mg.9
Therapeutic Index and Toxicity
The main toxic effects of codeine are central nervous system
(CNS) and respiratory depression, both of which stem from the
conversion of codeine to morphine by CYP2D6.10,11
Codeine is not listed on the official list of narrow ther-
apeutic index (NTI) drugs published by the National Insti-
tute of Health Sciences in Japan (http://www.nihs.go.jp) or
in the NTI drug list of the US FDA published in 1988
(http://ecapps.health.state.pa.us). However, it is difficult to de-
termine the therapeutic index of codeine, as both the effective
and lethal dose are highly dependent on the genetic polymor-
phism of CYP2D6: the alleles CYP2D6 may be characterized
as having normal function, reduced function, or nonfunctional
based on the expected activity level of the enzyme for which
they encode. Each functional group is assigned an activity value
ranging from 0 to 1.0 (e.g., 0 for nonfunctional, 0.5 for reduced
function, and 1.0 for fully functional). These values are used
to assign a total activity score for each genotype; the major-
ity of patients have an activity score of 1.0–2.0 and present
an extended metabolizers (EM) phenotype. Roughly 2% of pa-
tients have an activity score greater than 2.0 and are ultra-
rapid metabolizer (UM), whereas patients with activity scores
of 0.5 and 0 are intermediate metabolizers and poor metabo-
lizers, respectively.11,12 This polymorphism has significant in-
fluence on the efficacy and toxicity.13 Indeed, cases of toxicity
on the one hand and lack of therapeutic effect on the other
hand have been documented, even when the standard dose was
administered.10,14,14–16 As a result, the expectedCYP2D6pheno-
type of the individual patient, as well as the specific population,
must be taken into account whenever codeine administration
is considered.11
METHODS
Literature Analysis
Literature data were obtained from PubMed, Micromedex, the
Merck Index, and Goodman and Gilman’s “The pharmacologi-
cal basis of therapeutics” (11th edition). The keywords used for
searching were: codeine, intestinal absorption, BA, BE, log P,
solubility, permeability, pharmacokinetics, polymorphism, 2D6,
mass balance, metabolism, and radiolabeled studies.
Solubility Experiments
For the solubility experiments, a standard shake-flask method
was applied using three different aqueous media with pH val-
ues of 1.0 (maleate buffer), 4.5 (acetate buffer), and 7.5 (phos-
phate buffer) at 37◦C. Solubility studies were performed at the
Department of Clinical Pharmacology, Ben-Gurion University
of the Negev, Beer-Sheva, Israel, using analytical grade codeine
phosphate (generously donated by Rekah Pharmaceutical In-
dustry Ltd., Holon, Israel). The establishment of equilibrium
was confirmed by comparison of 24- and 48-h samples. The pH
was measured both before and after the experiment, to assure
that the solubility was indeed registered at the correct pH.
Drug levels in the samples were analyzed by ultraperformance
liquid chromatography (UPLC), using a previously described
method.17 Three replicates were carried out in each pH condi-
tion.
Permeability Experiments
The effective permeability coefficient (Peff) of codeine versus
metoprolol was determined in situ using the single-pass rat in-
testinal perfusion model. The experimental procedure followed
previous reports.18–20
To account for the complexity of the whole of the small in-
testine, permeability was determined in three different 10-cm
segments: a proximal jejunal segment, mid-small intestinal
segment, and a distal ileal segment.21–23 Briefly, each intesti-
nal segment was cannulated on two ends, and was perfused
with the corresponding phosphate buffer containing codeine
and metoprolol. The concentrations of codeine and metoprolol
in the perfusion buffers were 240 and 400 :g/mL, respectively,
to represent the maximal dose of the drugs (60 and 100 mg,
respectively) in 250 mL. The physiological pH of the perfused
small intestinal region dictated the pH throughout the experi-
ment: (1) proximal jejunum, pH 6.5; (2) middle small intestine,
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pH 7.0; and (3) distal ileum, pH 7.5.24 Steady-state conditions
were ensured by conducting an initial 60-min perfusion, fol-
lowed by additional 60 min with samples taken every 10 min
and immediate UPLC analysis.17 At the end of the experiment,
the length of each perfused intestinal segment was accurately
measured.25,26 Additionally, the pH of the collected samples was
measured to verify that there was no pH change during the per-
fusion.
The Peff (cm/s) through the rat gut wall was determined ac-
cording to the following equation:
Peff =
−Qln(C′out/C′in
)
2BRL
whereQ is the perfusion buffer flow rate (0.2 mL/min),C′out/C′in
is the ratio of the outlet and the inlet concentration of drug that
has been adjusted for water transport,27–29 R is the radius of
the intestinal segment (set to 0.2 cm), and L is the length of the
perfused intestinal segment.
CHEMICAL PROPERTIES
Polymorphism
No information on whether codeine exhibits polymorphism
in the solid state could be identified in the literature. One
should not confuse this term with the genetic polymorphism
of the metabolic enzyme CYP2D6, which is involved with the
metabolism of codeine and is discussed hereinafter.
Dosage Form Strengths and Dose
Oral dosage forms that contain codeine phosphate as the
only active ingredient exist in several countries, with dosage
strength that ranges between 15 and 60 mg.
The WHO (http://www.who.int), and Canadian guideline for
safe and effective use of opioids for chronic noncancer pain9
register a maximal dose of 30 mg for codeine phosphate, al-
though the Clinical Pharmacogenetics Implementation Consor-
tium (CPIC) guidelines specify a maximal dose of up to 60 mg
every 4 h.11
Solubility
The Merck Index and Martindale report codeine phosphate
as being “freely soluble in water.” Because the solubility
data for codeine phosphate available in the literature do not
cover the pH range of 1.0–7.5 at 37◦C, as required by the
FDA guidelines,30 additional solubility investigations were per-
formed to classify its solubility properties according to the Bio-
pharmaceutics Classification System (BCS).
According to the FDA, a drug substance is considered highly
soluble when the highest dose strength is soluble in 250 mL or
less of aqueous media over the pH range of 1–7.5. This can be
demonstrated through the calculation of the dose number (D0)
according to the equation:
D0 = M/V0/CS
where M is the highest dose strength, V0 is set at 250 mL, and
CS is the equilibrium solubility of the drug. A D0 value of ≤1
means that the highest dose strength is soluble in 250 mL of
the investigated aqueous media, and hence indicates “high sol-
ubility.” For codeine phosphate, with highest dose strength of
Table 1. Physiochemical Properties of Codeine Phosphate
Dosage Range Up to 60 mg
Solubility More than 120 mg/mL throughout
the pH range of 1–7.5
log P 1.1
pKa 8.2
Ionization state Base
log D6.5 0.25
log D7.5 0.6
60 mg, the minimal solubility that would lead to the “high solu-
bility” classification is 0.24 mg/mL.We found that the solubility
of codeine exceeded 120 mg/mL throughout the pH range of 1–
7.5, which means that the D0 of codeine is lower than 0.002,
unequivocally indicating a BCS high-solubility classification.
Partition Coefficient
Codeine is a moderately lipophilic compound and has a log P
value of 1.1 (octanol–water).31 At the small intestinal pH, 6.5–
7.5, codeine has positive log D values, ranging from 0.25 (log
D6.5) to 0.6 (log D7.5) (Table 1).
pKa
Codeine is a weak base and has a pKa value of 8.2.32
PHARMACOKINETIC PROPERTIES
Absorption and BA
Codeine has a relatively low BA (50%),1 which is likely because
of the extensive first-pass effect rather than poor absorption.
Indeed, codeine’s human fraction of dose absorbed (Fabs) was
reported to be high (>90%) based on cumulative urinary ex-
cretion of drug and drug-related material (chiefly codeine-6-
glucuronide), following oral administration.33–36 Although no
studies with radiolabeled codeine could be found in the litera-
ture to support Fabs, the high-cumulative urinary excretion of
drug and drug-related material is a very strong evidence for
Fabs. Passive permeation is probably the main mechanism re-
sponsible for the absorption of codeine, as no information on
transporter-mediated absorption of codeine could be found in
the literature. Moreover, similar apical to basolateral (a→b)
and basolateral to apical (b→a) permeability of codeine across
Caco-2 cell monolayers was reported.35 As the involvement of
transporters, either efflux or uptake, may result in an asym-
metrical permeability, the similar a→b and b→a permeabil-
ity suggests passive absorption,37,38 although it is recognized,
theoretically at least, that trade-offs, for example, between si-
multaneous efflux and influx transporters, could balance each
other. Similar absorption of oral and rectal dosage forms of
codeine39 also suggests passive permeability as the main ab-
sorptive mechanism, because the expression of transporters is
very unlikely to be similar in the small intestine and in the
colon.40 Neither dose linearity nor food effect studies for codeine
phosphate are available in the literature.
Permeability
The permeability of codeine across Caco-2 cell monolayers was
assessed by Skolnik et al.35 The apparent permeability (Papp)
of codeine was 2.29 × 10−5 cm/s in the a→b direction and
1.99 × 10−5 cm/s in the b→a direction. In comparison, the Papp
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Table 2. Effective Permeability Values (Peff, ×10−5 cm/s) Obtained
for Codeine and Metoprolol After In Situ Single-Pass Perfusion to the
Rat Proximal Jejunum at pH 6.5, Middle Small Intestine at pH 7.0,
and to the Distal Ileum at pH 7.5
Proximal
Jejunum;
pH 6.5
Middle Small
Intestine; pH 7.0
Distal Ileum;
pH 7.5
Codeine 3.5 (0.7) 7.8 (1.9) 13.1 (1.1)
Metoprolol 3.6 (1.1) 7.2 (0.9) 12.6 (2.8)
Mean (SD); n = 6 in each experimental group.
of metoprolol, the benchmark for low/high permeability class
boundary, was 1.77 × 10−5 cm/s in the a→b direction and 9.28
× 10−6 cm/s in the b→a direction. For further comparison, val-
ues for the low-permeability drug cimetidine were 1.64 and 8.58
× 10−6 cm/s in the absorptive and secretory directions. Thus,
the permeability of codeine exceeds that of metoprolol, in the
same laboratory, and codeine is therefore classified as a high-
permeability drug according to this study. Furthermore, the
similar permeability of codeine in both the absorptive and se-
cretory directions indicates that themainmechanism of codeine
absorption is passive permeation, with little or no involvement
of transporters.
To further validate this result, we conducted in situ perme-
ability studies of codeine phosphate versus metoprolol using
the single-pass rat intestinal perfusion method.
The experimental procedure followed previous reports.18–20
Similar permeability was revealed for codeine and metoprolol
throughout the entire small intestine; codeine and metoprolol
permeability values were 3.5 × 10−5 and 3.6 × 10−5 cm/s in the
proximal jejunum, 7.8 × 10−5 and 7.2 × 10−5 cm/s in the middle
small intestine, and 1.3 × 10−4 and 1.2 × 10−4 cm/s in the
distal ileum, respectively (Table 2). These results corroborate
the findings of Skolnik et al.35 and provide further evidence
that codeine is a high-permeability drug.
Distribution, Metabolism, and Elimination
Codeine has a volume of distribution (Vd) of 3–7 L/kg and is
widely distributed throughout the body.34,41 Codeine is exten-
sively metabolized by the liver, predominantly to codeine-6-
glucoronide, and in small part to norcodeine by CYP3A4.34,42 A
small fraction of codeine is converted by CYP2D6 to morphine,
which is responsible for both the pharmacological activity and
toxic effects of codeine.34,41–44 Only about 3%–5% of codeine
dose is excreted unchanged in the urine.33,34,42 The elimination
half-life of codeine was reported to be 1.8 h.34 Quite variable
clearance was reported in the literature, ranging from 40 to
140 L/h.34,42,44–48
DOSAGE FORM PERFORMANCE
Excipients
The excipients of several marketed IR solid oral drug products
containing codeine phosphate as single API are given in Table 3.
No specific studies about possible effects of these excipients
on codeine release and absorption have been reported to date.
Moreover, the products are marketed in ICH associated coun-
tries, and hence, one may assume that they have passed a
rigorous BE study, indicating that the excipients, in the
amounts used, do not interfere with codeine absorption.
In Vivo BE
No BE studies of drug products containing codeine as a single
API were found in the literature. However, several IR combi-
nation drug products containing codeine phosphate have been
demonstrated to be bioequivalent and the results are summa-
rized in Table 4.
In an open, two treatment, two period crossover study in 24
subjects, a test product containing aspirin, butalbital, caffeine,
and codeine (325/50/40/30 mg) produced by Jerome Stevens
was found to be bioequivalent to a reference product (Sandoz’s
Fiorinal); The dose used in the study consisted of two capsules
from each product, bringing the total administered dose of
codeine to 60 mg. The 90% confidence interval (CI) values of
the test to reference (T/R) ratios for AUC0–t, AUC0–∞, and Cmax
for codeine were 0.92–1.08, 0.93–1.06, and 0.99–1.14, respec-
tively (www.accessdata.fda.gov/drugsatfda docs/anda/98/74–
951 Butalbital,%20Aspirin,%20Caffeine,%20and%20Codeine%
20Phosphate Bioeqr.pdf).
An additional two-way crossover BE study between a similar
combination drug product (aspirin, butalbital, caffeine, and
codeine; 325/50/40/30 mg) manufactured by Endo pharmaceu-
ticals and the same reference formulation (Sandoz’s Fiorinal)
was performed in 24 subjects. Again, the total administered
dose of codeine was 60 mg. The 90% CI values of the test
to reference (T/R) ratios for AUC0–t, AUC0–∞, and Cmax for
codeine were 0.98–1.10, 0.99–1.11, and 0.95–1.14, respec-
tively (www.accessdata.fda.gov/drugsatfda docs/nda/99/75–
351 Butalbital bioeqr.pdf).
A randomized, single dose, open-labeled two-period
crossover study compared a test formulation of ibuprofen
and codeine (200/12.8 mg) produced by The Boots Company
PLC (UK) to the reference formulation Nurofen Plus (Crookes
Healthcare Limited, UK). The 90% CI values of the test to
reference (T/R) ratios for AUC0–t, AUC0–∞, and Cmax for codeine
were 0.91–1.00, 0.91–1.00, and 0.86–0.97, respectively (www.
mhra.gov.uk/home/groups/par/documents/webysiteresources/
con103096.pdf).
It should be noted that the dissolution of the products de-
scribed above follows the USP requirements, but does not meet
the FDA biowaiver dissolution criterion.
Dissolution
In the first two aforementioned BE studies, a dissolution as-
say was performed under the conditions specified by the USP
for capsules containing the combination aspirin, butalbital, caf-
feine, and codeine. The tests were run usingUSP apparatus 2 in
50 rpm for 60 min, with a medium of 1000 mL of water. In both
studies, both the reference and the test products met the USP
dissolution requirements of minimum 75% of the amount of ac-
tive ingredients dissolved within 60 min. The third BE study
did not specify whether dissolution studies were conducted.
DISCUSSION
Solubility
Taking 60 mg as the highest dose strength of codeine, the min-
imal solubility that would allow the “high solubility” classifi-
cation is 0.24 mg/mL. We found that the solubility of codeine
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Table 3. Excipientsa Present in Codeine Phosphate IR Solid Oral Drug Productsb with a Marketing Authorization (MA) in Canada (CA),
Czech Republic (CZ), Germany (DE), Denmark (DK), Spain (ES), France (FR), Ireland (IE), The Netherlands (NL), Norway (NO), Romania
(RO), Sweden (SE), Slovakia (SK), and United Kingdom (UK)c, and the Minimal and Maximal Amount of that Excipient Present per Dosage
Unit in Solid Oral Drug Products with a MA in the USd
Excipient
Drug Products Containing That Excipient with
a MA Granted by the Named Country
Range Present in Solid
Oral Dosage Forms with
a MA in the US (mg)
Acacia UK(1) 5–156
Calcium hydrogen phosphate ES(2) 104–850
Cellulose, microcrystalline CA(3,4), DK(5,6), ES(2), FR(7), IS(8), NL(9), NO(10), RO(11), and SE(12) 4.6–1385*
Cellulose, powdered DE(13) 44–170
Croscarmellose sodium CA(3) 2–180
Crospovidone DE(14) 4.4–792*
Ethylcellulose DE(15) 1.0–121*
Gelatin CZ(16), DE(15), DK(5,6,17), IS(8), NO(10), RO(18,19), SE(12), and SK(20) 1 – 756*
Hypromellose DK(6) and NO(10) 0.8–537
Lactose CA(3,4), CZ(16), DE(13,14,21,22), DK(5,6,17), IE(23), IS(8), NL(9,24), NO(10),
RO(11,18,19,25–27), SE(12), SK(20), and UK(1,28)
23–1020*
Magnesium stearate CA(3,4), CZ(16), DE(13–15,21), DK(5,6,17), ES(2), FR(7), IE(23), IS(8), NL(9,24),
NO(10), RO(11,18,19,25–27), SE(12), SK(20), and UK(1,28)
0.15–401*
Povidone DE(14,15) and RO(25,26) 0.17–240
Propylene glycol DK(6) and NO(10) 1.5–148
Silica CA(3,4), DE(13,22), ES(2), IE(23), NL(9), and RO(11,26) 0.50–100
Sodium laurilsulfate DE(15) 0.65–52
Sodium starch glycolate DE(13) and ES(2) 2–876*
Sodium metabisulfite IS(8) and SE(12) 0.36–8
Sorbitol DE(13) 5–337
Starch CZ(16), DE(21,22), DK(5,6,17), IS(8), NL(9,24), NO(10) RO(11,18,19,25–27), SE(12),
SK(20), and UK(1,28)
0.44–1135*
Starch, pregelatinised UK(28) 4.2–600
Stearic acid CA(4), DE(22), and UK(1,28) 0.9–72*
Sucrose DE(15) 12–900
Talc CZ(16), DE(15,21), DK(5,6,17), ES(2), IS(8), NL(9), NO(10), RO(11,18,19,25–27),
SE(12), and SK(20)
0.1–220*
aColourants, water, and ingredients present in the coating are not included. Substances are excluded if it can be assumed that the constituents are only present
in the coating/polish.
bExcluded are: combination products.
cSources of data: CA, www.hc-sc.gc.ca (accessed 28-01-2014); CZ, www.sukl.cz/ (accessed 28-01-2014); DE, www.rote-liste.de; (accessed 29-01-2014); DK,
www.dkma.dk (accessed 29-01-2014); ES, www.aemps.es (accessed 29-01-2014); FR, www.theriaque.org/; (accessed 29-01-2014); IE, www.imb.ie/ (accessed 04-02-2014);
IS, www.serlyfjaskra.is (accessed 04-02-2014) NL, www.cbg-meb.nl. (accessed 05-02-2014); NO, www.legemiddelverket.no/ (accessed 05-02-2014); RO, www.anm.ro/
(accessed 05-02-2014); SE, www.lakemedelsverket.se (accessed 05-02-2014); SK, www.sukl.sk (accessed 05-02-2014); UK, www.medicines.org.uk/emc/ (accessed 10-
02-2014).
dUS: FDA’s Inactive Ingredient Database, http://www.fda.gov/Drugs/InformationOnDrugs/ucm113978.htm (version date: September 16, 2013).
*The upper range value reported is unusually high for solid oral dosage forms and the authors doubt its correctness.
1. Codeine phosphate 15/−30/−60 mg tablets (Wockhardt UK Ltd.).
2. Codeisan 28.7 mg comprimidos.
3. CODEINE 15/−30 (codeine phosphate tablets, USP 15/−30 mg) (LABORATOIRES TRIANON INC.).
4. Nratio-CODEINE (codeine phosphate tablets USP 15/−30 mg) (Teva Canada Limited).
5. “Kodein” “Alternova,” filmovertrukne tabletter.
6. Kodein “DAK,” filmovertrukne tabletter.
7. PADERYL 19.5 mg CPR.
8. Kodein Recip 25 mg to¨flur.
9. Codeı¨nefosfaat 10/−15/−20 PCH, tabletten 10/−15/−20 mg.
10. Kodein 25 mg tabletter.
11. CODEINA˘ FOSFORICA˘.
12. Kodein Recip 25 mg tabletter.
13. Codeinum phosphoricum Berlin–Chemie tabletten.
14. codi OPTR© tabletten.
15. Tussoret R© Tag-/Nacht–Kapseln.
16. Codein Slovakofarma 15/−30 mg.
17. Kodein “SAD,” tabletter.
18. Codeina˘ Fabiol 15 mg, comprimate.
19. FOSFAT DE CODEINA˘ 15 mg comprimate.
20. Codein-SLOVAKOFARMA 15/−30 mg.
21. Codeinum phosphoricum ComprenR© 30 mg/-forte ComprenR© 50 mg tabletten.
22. Codipertussin mite tabletten codeinum phosphate 30 mg/codipertussin tabletten codeinum phosphate 50 mg.
23. Codant 30 mg tablets.
24. Codeı¨nefosfaat ratiopharm 10/−20 mg, tabletten.
25. CODEINA˘ FOSFAT 15 mg comprimate.
26. CODEINA˘ FOSFAT LPH 15 mg comprimate.
27. CODEINA˘ FOSFAT MCC 15 mg comprimate.
28. CODEINE PHOSPHATE TABLETS BP 15/−30/−60 mg (Actavis UK Limited).
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exceeded 120 mg/mL throughout the pH range of 1–7.5, which
means that theD0 of codeine is lower than 0.002, unequivocally
indicating a BCS high-solubility classification.
Permeability and Absorption
Codeine has a human intestinal absorption of more than
90% based on cumulative urinary excretion of drug and
drug-related material (chiefly codeine-6-glucuronide) following
oral administration.33–36
Codeine was previously classified as high-permeability drug
in Caco-2 monolayers study.35 This result was further strength-
ened by our rat perfusion study in three different segments
throughout the small intestine, which showed that the perme-
ability of codeine is similar to the reference drug metoprolol
throughout the entire small intestine. Taken together, these
results indicate that codeine may be safely classified as a high-
permeability drug.
BCS and BDDCS Classification
Previously, Skolnik et al.35 classified codeine as a BCS class 1
drug based on its high permeability across Caco-2 monolayers.
Additional publications also classified codeine as a BCS class 1
compound.17,36,49–51
On the contrary, Kasim et al.52 and Takagi et al.53 used par-
tition coefficient values for the classification of drug perme-
ability, and because codeine’s log P (1.1) value is lower than
that of the reference drug metoprolol (2.3),23 they provision-
ally classified codeine phosphate as a BCS class 3 drug. In
general, a reasonable correlation exists between log P val-
ues and jejunal permeability; however, a significant number
of false-negative cases have been recorded, in which drugs with
lower log P than metoprolol exhibit complete absorption. These
include antipyrine, cephalexin, D-glucose, levodopa, L-leucine,
phenylalanine, piroxicam, valacyclovir,52,53 pseudoephedrine,23
and sotalol,22 indicating the difficulty of assigning BCS
classification based merely on limited physicochemical
characteristics.
On the basis of the urinary recovery data in humans, the
work of Skolnik et al.,35 and the experimental data presented in
thismonograph, it can be concluded that codeine phosphate can
be safely classified as aBCS class 1 drug. Benet et al.54 classified
codeine as a class 1 compound according to the Biopharmaceu-
tics Drug Disposition Classification System (BDDCS) because
of its high fraction of dose metabolized.
Risks of Bioinequivalence Caused by Excipients and/or
Manufacturing Parameters
No information was found in the literature concerning poten-
tial influence of excipients or manufacturing process on the
performance of codeine formulations.
Patient’s Risks Associated with Bioinequivalence
The main risk associated with bioinequivalence of generic
codeine formulations is codeine toxicity (i.e., CNS and respi-
ratory depression) that is related to the conversion of codeine
to morphine and is highly dependent on the CYP2D6 pheno-
type. The fraction of codeine dose converted to morphine is
5%–10% in EM42; however, the amount of codeine converted
to morphine may be higher in UM by as much as 80-fold com-
paredwith EM.10,15 For this reason, the CPICGuidelines advise
against the use of codeine in patients that were found to be UM
by genetic screening.11 This complication, however, is present
irrespective of the dosage form, and hence is unrelated to BE
considerations.
It should also be noted that codeine has long been recog-
nized as a drug of abuse, and despite this, it is incorporated
in many OTC drug products. Again, the potential for abuse is
irrespective of the dosage form, and hence should not be re-
garded as to BE considerations.
CONCLUSIONS
Codeine phosphate is a high-solubility, high-permeability drug,
and is therefore classified as a BCS class 1 compound. The risk
of bioinequivalence is manageable as long as the use of codeine
is avoided in UM. For these reasons, we consider codeine phos-
phate to be a good candidate for waiver of in vivo BE studies.
Granting a biowaiver for IR solid oral dosage forms contain-
ing codeine phosphate is scientifically justified, subjected to the
following conditions: (1) the test product contains only excipi-
ents that are well known and used in normal amounts, for ex-
ample, those tabulated for products with MA in ICH-associated
countries (Table 3); and (2) both the test and comparator dosage
forms enable very rapid dissolution of codeine, or, rapid disso-
lution with similarity of the dissolution profiles demonstrated
at least at pH 1.2, 4.5, and 6.8 for codeine. For products con-
taining other API(s) in addition to codeine, the possibility of a
biowaiver for each API should be separately considered.
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